Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250272) titled 'A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis' on Aug. 1.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, active control, parallel assignment, treatment purpose
Primary Sponsor: Inoue Ayano
Condition:
Diffuse Cutaneous Systemic Sclerosis
Intervention:
Experimental: VAY736 (Ianalumab)
Treatment Period 1:
Ianalumab subcutaneous (s.c.) injection as defined in the protocol
Treatment Period 2:
Open-label Ianalumab subcutaneous (s.c.) injection as defined in the protocol
Placebo Comparator: Placebo
Treatment Period 1:
Plac...